CLDX
Celldex Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.64B
P/E Ratio
—
EPS
$-4.04
Beta
1.20
52W High
$34.52
52W Low
$16.74
50-Day MA
$27.75
200-Day MA
$25.46
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Fundamentals
| Revenue (TTM) | $1.54M |
| Gross Profit (TTM) | $-243.53M |
| EBITDA | $-283.99M |
| Operating Margin | -72027.00% |
| Return on Equity | -40.60% |
| Return on Assets | -26.10% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $7.92 |
| Price-to-Book | 3.92 |
| Price-to-Sales (TTM) | 1707.40 |
| EV/Revenue | 1003.66 |
| EV/EBITDA | -17.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.70% |
| Shares Outstanding | $78.46M |
| Float | $61.26M |
| % Insiders | 0.15% |
| % Institutions | 96.75% |
Historical Volatility
HV 10-Day
52.55%
HV 20-Day
50.12%
HV 30-Day
76.51%
HV 60-Day
65.62%
HV Rank
81.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($54.33 target)
1
Strong Buy13
Buy1
Hold1
Strong SellData last updated: 4/10/2026